AOD-9604
300 mcg · Daily
Robert
Founder, F*CK Getting Old — independent researcher, not a medical professional.
Last reviewed · 3 cited sources
Evidence
- Human Studies
- 8
- Animal Studies
- 20
- Clinical Status
- Research
- Confidence
- Low
- Long-Term Safety
- Reasonably well-tolerated in the Phase 2 trials that were conducted, but those trials did not demonstrate the intended fat-loss benefit
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
AOD-9604 is a modified, more stable version of HGH Fragment 176-191, developed specifically to be tested as an anti-obesity drug. Its pharmaceutical development for that use was discontinued after Phase 2b trials failed to show a meaningful weight-loss benefit over placebo, though it was later approved in Australia as a novel food ingredient (not as a medicine).
Common Protocols
- 300 mcg subcutaneous daily, per informal research-community protocols — note the drug-development trials for weight loss specifically did not succeed
Side Effects
- Injection site irritation
- Generally reported as well-tolerated in the trials that were run
Interactions
- No formal interaction data exists
Practical Details
- Cost
- $$
- Typical Vial Size
- 5 mg
- Storage
- Refrigerate after reconstitution
Key Studies & Reviews
- Wilding J (2004). AOD-9604 Metabolic. Curr Opin Investig Drugs. PMID 15134286.
- Ng FM et al. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. PMID 11146367.
- Dominikowski A et al. (2026). The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis. Front Endocrinol. PMID 42395176.
Search the Research
AOD-9604 FAQ
What is the typical AOD-9604 dosage?
Commonly reported protocols: 300 mcg subcutaneous daily, per informal research-community protocols — note the drug-development trials for weight loss specifically did not succeed. Our reference entry uses 300 mcg, Daily. These reflect protocols reported in research and user communities, not a medical recommendation — dosing should be decided with a clinician.
What are the side effects of AOD-9604?
Reported side effects include: Injection site irritation; Generally reported as well-tolerated in the trials that were run.
Is AOD-9604 FDA approved?
AOD-9604 is not FDA approved for human use and is generally sold as a research chemical, so purity and dosing are not regulated.
How much research is there on AOD-9604?
Our evidence profile counts roughly 8 human and 20 animal studies, with low overall confidence. Long-term safety: Reasonably well-tolerated in the Phase 2 trials that were conducted, but those trials did not demonstrate the intended fat-loss benefit.
Does AOD-9604 interact with other drugs or supplements?
No formal interaction data exists.
How do I reconstitute AOD-9604?
A common setup is a 5 mg vial mixed with 2 mL of bacteriostatic water, which puts a 300 mcg dose at about 6 units on a U-100 insulin syringe. Use the reconstitution calculator with your own vial and dose to get exact numbers. Storage: Refrigerate after reconstitution.
Related compounds
Modified HGH fragment 176-191; approved as a novel food ingredient in Australia, not as a drug